AbbVie to Highlight its Innovative Pipeline to the Investment Community

NORTH CHICAGO, Ill., June 3, 2016 /PRNewswire/ -- At an R&D Day meeting today for the investment community, AbbVie (NYSE: ABBV), a global biopharmaceutical company, will present an overview of its innovative pipeline that reinforces AbbVie's strategy of delivering new therapies that significantly advance and reset the standard of care. Many current therapies in oncology, immunology, virology, neuroscience and women's health are insufficient in meeting the medical needs of patients. In addition, many of the diseases in these therapeutic areas are debilitating, life-threatening and cause a significant burden on healthcare systems around the world.

"Since becoming an independent company in 2013, AbbVie has developed a robust and diversified pipeline focused on diseases that have compelling medical needs," said Richard A. Gonzalez, chairman and chief executive officer, AbbVie. "AbbVie's R&D pipeline of more than 50 active clinical development programs has AbbVie poised to deliver a consistent stream of innovative new medicines for patients while driving long-term growth through 2020 and beyond."

AbbVie's late-stage pipeline consists of multiple assets, both approved and investigational, that have generated data to-date demonstrating the potential to improve the standard of care. Over the next five years, AbbVie intends to advance the treatment of patients with cancer, multiple sclerosis, rheumatoid arthritis, Crohn's disease, psoriasis, HCV, endometriosis and uterine fibroids.

As part of AbbVie's R&D Day program, the company will present information on the following late-stage programs: Rova-T* (rovalpituzumab tesirine), IMBRUVICA® (ibrutinib), VENCLEXTA™ (venetoclax), ABT-494*, Risankizumab* (BI655066), next-generation HCV treatments (ABT-493* + ABT-530*), endometriosis and uterine fibroids (Elagolix*) and ZINBRYTA™ (daclizumab). Additional information regarding Veliparib* and ABT-414* also will be included in the R&D Day program.

"AbbVie's late-stage pipeline has the potential to deliver more than 20 new medicines or indications by 2020, with the approval of seven new medicines or indications expected in 2016," said Michael Severino, M.D., executive vice president, research & development and chief scientific officer. "These new medicines, combined with our early-stage clinical programs, have the potential to address medical need, elevate the standard of care and improve patient outcomes."

AbbVie's early-stage pipeline leverages the company's investments in early discovery, genomics, novel biology and enabling technologies that drive AbbVie's focus on identifying new therapies that can reset the standard of care in oncology, immunology and neuroscience. AbbVie's goal with these programs is to drive deep and durable disease control that improves patients' outcomes and significantly reduces the burden on the healthcare system.

Early-stage pipeline presentations will focus on immunology, oncology, immuno-oncology, multiple sclerosis and spinal cord injury (ABT-555*), Alzheimer's disease, and enabling technologies such as bispecifics (biological therapies that bind to two different targets with the goal of enhanced effectiveness in treating diseased tissues).

Webcast Details
A webcast of AbbVie's R&D Day meeting will be available through AbbVie's investor relations website at www.abbvieinvestor.com on June 3, 2016, from 9:00 a.m. – 1:00 p.m. CT.  Full copies of the presentation, speaker biographies and other supporting information will also be available on www.abbvieinvestor.com.

* Rova-T, Veliparib, ABT-414, ABT-494, Risankizumab (BI 655066), ABT-493, ABT-530, ABT-555 and Elagolix are investigational compounds and their efficacy and safety have not been established by the FDA or any other health authority.

About AbbVie
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

Forward-Looking Statements
Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2015 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

SOURCE AbbVie

Related Links

http://www.abbvie.com